When you have time, go to REGN message boards and tell them about OCAT. There is a lot of money parked over there which should buy a little OCAT insurance imho.
If REGN can go to $500/share with 100M shares outstanding in an indication with a much smaller market, then OCAT should be able to easily hit that price with only 40M shares outstanding and a much larger target market..
Smart REGN investors would consider selling 20% of their REGN holdings and putting that money to work in OCAT. If REGN can go to $500/share with 100M shares outstanding. Ocat can easily go to $1000/share with 40M shares outstanding. The Dry AMD market is much larger than the Wet AMD market, and OCAT has more than 50% less shares outstanding. Further OCAT owns all the rights to its technology for Dry AMD.
And if you fix the Dry indication, you stop patients from getting the Wet version. Not good for REGN and Eylea(tm) with OCAT's RPE cell therapy on the road to approval both here and in Europe.
From the OCAT board:
"Just think about this, if you stop the natural progression of dry amd, you are essentially preventing the advancement of the disease to the wet form. We have all heard of lucentis and eylea by now - both multibillion dollar drugs used to treat the wet form of amd. The dry form has nearly nine times the wet amd population. Ocata's cell treatment will eliminate the need for anti-vegf drugs like eylea and lucentis. Ocata doesn't even need to reverse blindness - although that is something that has happened to greater than 50% of the treated patients in phase one - because halting the progression is far better than anything in existence. Halting the disease is enough to wipe out the wet amd market. If Ocata commercializes in 2019, houses of cards will start falling pretty quickly. The market opportunity for SMD isn't going to be chump change when you consider market exclusivity with an orphan indication. The revenue from SMD will open the flood gates for the company. They will in all likelihood 'own the eye'."
You sure summed it up well hschlauch. Everyone who is long OCAT needs to go over to the REGN board and explain this to them. REGN shareholders should sell 20% of their position and use the funds to buy OCAT. Doing so is buying REGN insurance, while also having the chance to make a fortune in the meantime.
People are moving their cash over to OCAT. It has much more potential and it has a therapy that can put an end to WET macular degeneration.
You are absolutely correct. In dry age-related macular degeneration (AMD) OCAT has demonstrated safety and efficacy (you don't get your vision back by happenstance or placebo effects) and has a sound IP position with money in the bank and no debt. There also are very few shares outstanding, and there is no opportunity for bad news on the horizon. Any person who owns REGN should take out OCAT insurance since OCAT has RPE cell therapy which can put REGN's wet degeneration product out of business. If you don't fix DRY macular degeneration, you don't get WET, as least that is my understanding. Take 25% of your REGN holdings and buy OCAT insurance to protect yourself and perhaps make some $$ in the process.
Why doesn't Comcast get NBC to reveal the Obama administration's involvement in the Charleston shooting hoax. No one was killed, but Obama goes on TV and says it is so. Oh you didn't know it was a hoax. I guess you didn't see the Department of Homeland Security's announcement that they were running a live shooter drill in Charleston on the same day as the shooting. It is posted on their website. And it is impossible to kill 9 people with a pistol and only injure one. No marksman is that good, especially with moving targets seeking to preserve their lives.
I should have added that the newly proposed system is particularly troublesome for a high flying P/E stock like UPS. Everything has to hit on all cylinders perfectly to keep the stock moving up. A loss of AMZN business is a BIG deal when the P/E is around 30.
The new system Amazon is proposing will cut UPS out of the circle. UPS uses highly paid union labor to deliver AMZN packages. AMZN can save a lot of money by switching to non-union contract labor for package delivery. Uber IS working for taxi service. The advent of Uber type drivers for package delivery will be a huge hit to UPS revenue. The recent announcement will become a serious problem for UPS and its shareholders. Mark my words.
As a number of us opined openly during the PVG share price take down, Strathcona never had the appearance of a legitimate franchise, hired to give PVG a sound resource estimate. PVG already had that coming from the very well know firm Snowden. There was no need to hire the additional Strathcona, no reason at all. And those of us who investigated this company could find nothing showing that it was a real operating enterprise capable of doing what is was purportedly hired to do. All of this, of course, brought into question Quartermain's integrity and his personal associations.
Strathcona was in fact involved in the Bre-x scandal, which also raised questions of its associations, particularly with those of the likes of intelligence agencies like the CIA. Bre-X had an intelligence agency footprint from beginning to end. And of course, these things are planned from beginning to end, and Strathcona was a part of it. And then we had the two guys who showed up on this board, repeatedly bashing PVG until the very date that the Snowden results were published and the stock started its recovery.
Not to toot my whistle too much, but I smelled the rat from the beginning, and when I saw Strathcona involved in the Bre-X scandal, I knew that the PVG takedown had to be orchestrated. In fact, I was so sure of it that I backed up the truck and bought as much PVG as possible. On the day the Snowden results were announced, I made more money that day on one stock than I ever had prior to that day. Perhaps Quartermain was forced to do what he did. We'll never know. That is how it is with CIA ops and secret societies. But one thing I do know is that there are a lot of crooked people involved in the markets. I have seen too many orchestrated take downs in my day. And at no point does the SEC go after these guys. The folks who do these things must be very long on connections but extremely short on smarts and morals. That is why they have to cheat.
Post split, the company only has a market capitalization of approximately $35 million. This is nothing considering that they sell about $60 million in oil at depressed prices.
The patient also adds "I know it takes a while for the hair cells to grow." "I am just too excited and hope it keeps getting better."
I just did a search that located a person's fb blog that has indications of hearing for the first time in his right ear. The patient says it is "it is so weird I can hear myself humming in the right ear ... it is so new for me." " I could never hear myself in the right ear before." I have tried to put the whole quote into this thread but the Yahoo system keeps removing my post. Nonetheless you can find it by searching for a Dr. Hinrich Staecker on hearing loss and how to bring it back.
PPHM has no partner. And it isn't an adjuvant to anything. It have not been approved for a single indication. You need to wait for the SUNRISE data, get it?
Okay so this is a company with good phase 1 data in indications that can bring in tens of billions of dollars. I won't give an estimate on the numbers because they are so high that they are outrageous. Given the data we have seen for phase 1, there doesn't seem to be a whole lot of doubt that the pivotal for Stargardt's and the P2 for AMD will show statistical significance. Since theRPEs have been shown to be safe in phase 1, there are only two more hurdles here: 1) the need to raise money, and 2) manufacturing. The former can be done with a partnership, and the latter is something I would like someone on this thread to comment on. Can the RPEs be made in quantities sufficient to meet the huge demand of the untapped AMD market?
biodoggie will look anywhere for dots to connect, even when they don't connect.
Look you numbskull, we are not on anyone's radar. Did you not see the front line data for lung cancer? It was nothing to write home about, and the second line data was flawed because of the vial switching and label changing. There is not a CEO in this world who would be looking to buyout such a risky investment.
You have to wait for SUNRISE. Please spare us all your nonsense.
Can anyone explain the discrepancy between the front line data and the second line therapy?
Why was the front line data nothing to write home about? And why did they never publish the OS front line data like they said they would?
March 9, 2012
Peregrine Reports Data From Phase II Front-Line Lung Cancer Trial
Promising Progression-Free Survival From Site Assessments; Overall Survival Endpoint From This Study Anticipated in Second Half of 2012
TUSTIN, CA -- (MARKET WIRE) -- 03/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced top-line overall response rate (ORR) and current median progression free survival (PFS) estimates from its phase II trial comparing bavituximab plus carboplatin and paclitaxel versus carboplatin and paclitaxel alone in patients with front-line Stage IIIb and Stage IV non-small cell lung cancer (NSCLC).
Based on investigator assessments, patients treated with bavituximab plus carboplatin and paclitaxel demonstrated a current median PFS estimate of 5.8 months versus 4.6 months in patients treated with carboplatin and paclitaxel alone, a 26% improvement. These results are consistent with a prior phase II single-arm study testing the same bavituximab combination in front-line NSCLC patients which showed a 6.1 month median PFS and with several prior published studies with carboplatin and paclitaxel in front-line patients that showed approximately a 4.5 month median PFS. Based on independent central imaging reads, patients demonstrated a current median PFS estimate of 6.7 months for the bavituximab-containing arm and 6.4 months for the chemotherapy-only arm. Peregrine expects to report median overall survival (OS) from this trial in the second half of 2012.
... While the data from the investigator assessments were in alignment with previous published reports for carboplatin and paclitaxel and suggested an encouraging difference between the treatment arms, the unexpected long PFS estimate for the control arm based on central reads confounds our ability to fully interpret this secondary efficacy endpoint," said Joseph Shan, vice president, clinical & regulatory affairs at Peregrine